Prevail Innovative Wealth Advisors LLC Purchases 6,937 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Prevail Innovative Wealth Advisors LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1,721.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,340 shares of the medical research company's stock after purchasing an additional 6,937 shares during the period. Prevail Innovative Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $3,652,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares in the last quarter. One Charles Private Wealth Services LLC boosted its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock worth $260,000 after purchasing an additional 20 shares in the last quarter. Holderness Investments Co. boosted its position in shares of Thermo Fisher Scientific by 1.7% in the 4th quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company's stock worth $664,000 after purchasing an additional 21 shares in the last quarter. Port Capital LLC boosted its position in shares of Thermo Fisher Scientific by 1.6% in the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after purchasing an additional 22 shares in the last quarter. Finally, Clark Capital Management Group Inc. boosted its position in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock worth $2,312,000 after purchasing an additional 23 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $425.44 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The stock's fifty day moving average is $409.45 and its 200 day moving average is $475.17. The stock has a market cap of $160.60 billion, a P/E ratio of 24.95, a P/E/G ratio of 2.31 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the firm earned $5.11 EPS. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent analyst reports. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Argus lowered their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Barclays lowered their price objective on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a research report on Tuesday, June 24th. Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Finally, Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research report on Friday. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average target price of $600.30.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.